Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Beyond Blood Sugar...

Beyond Blood Sugar Control: Diabetes Drug Sotagliflozin May Help Prevent Dangerous Blood Clots, Study Shows

Written By : Dr. Kamal Kant Kohli Published On 2026-10-30T11:15:37+05:30  |  Updated On 30 Oct 2026 4:27 PM IST
Beyond Blood Sugar Control: Diabetes Drug Sotagliflozin May Help Prevent Dangerous Blood Clots, Study Shows
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health.

Researchers at Michigan Medicine have uncovered a mechanism that may explain why sotagliflozin, an FDA-approved diabetes medication marketed as Inpefa, reduces the risk of heart attack and stroke. In a series of laboratory experiments, the research team found that the drug helps prevent excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain.

The findings, published in the Journal of Clinical Investigation, provide new insight into cardiovascular benefits of the drug that extend beyond blood sugar control.

“A drug that can both decrease the risk for diabetes along with the risk for having a heart attack or stroke could be a turning point in our ability safely treat this growing population in the US and abroad,” said Michael A. Holinstat, Ph.D., M.S., co-senior author and Professor of Pharmacology, Internal Medicine, and Surgery at University of Michigan Medical School.

Sotagliflozin and heart attack, stroke risk

Sotagliflozin belongs to a class of medications known as sodium-glucose cotransporter (SGLT) inhibitors, which lower blood sugar by blocking the proteins responsible for glucose reabsorption. Unlike the widely used SGLT2 inhibitors, which primary act in the kidneys, sotagliflozin, targets both SGLT2 proteins in the kidneys and SGLT1 proteins in other organs.

Over the past decade, SGLT2 inhibitors such as empagliflozin (Jardiance) and dapagliflozin (Farxiga), have become a mainstay of type 2 diabetes treatment. Over 20% of patients are taking the medications.

Sotagliflozin has demonstrated an unusual ability in clinical trials. Unlike medications that only target SGLT2, the drug reduced the risk of ischemic events such as heart attack and stroke.

To better understand why, researchers conducted a head-to-head comparison between sotagliflozin and the empagliflozin, or Jardiance. While sotagliflozin limited platelet activation in blood samples from both healthy volunteers and people with type 2 diabetes, empagliflozin had little to no effect.

The team also found that sotagliflozin made platelets less likely to stick together and form blood clots. In mice with injured blood vessels, the drug reduced clot formation by approximately 60%, compared with just 5-10% in animals treated with empagliflozin.

“These experiments showed that sotagliflozin has a unique effect, and blocking SGLT2 alone is not enough to inhibit platelet aggregation,” said Eugene Chen, M.D., Ph.D., co-senior author and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at U-M Medical School.

“Sotagliflozin may offer additional protection against blood clots, potentially lowering the risk of heart attack and stroke.”

What makes sotagliflozin different?

Researchers then asked whether SGLT1 inhibition alone could explain the drug’s anti-clotting effect.

Removing SGLT1 from platelets in mice reduced blood clot formation by about 40%. However, removing it genetically or blocking it with a SGLT1-selective inhibitor drug called mizagliflozin did not fully reproduce the effects of sotagliflozin.

This suggests that sotagliflozin may help prevent blood clots through additional mechanisms beyond blocking SGLT1 in platelets.

They also believe SGLT1 in endothelial cells, which line blood vessels, may influence platelet interactions and clot formation, a possibility that warrants further study.

“Sotagliflozin appears to be in the sweet spot because compounds that have higher levels of SGLT1-selective inhibitors can cause gastrointestinal issues,” said Bertram Pitt, M.D., co-author and Professor Emeritus of Internal Medicine at U-M Medical School.

“We think this could be a wonder drug with potential to offer benefit for many conditions.”

Sotagliflozin is approved for treatment in adults with heart failure, as well as those with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors.

Researchers say in future studies of the drug, they would also like to evaluate the effects on patients with other conditions, such as chronic kidney disease and atrial fibrillation.

“The search for medications that reduce the risk of life-threatening blood clots without increasing the risk of bleeding has continued for decades,” Holinstat said.

“Sotagliflozin has now been demonstrated to serve both functions and may represent the next advancement in prevention of blood clots, heart failure and stroke in patients with and without diabetes.”

Reference:

SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis,” Journal of Clinical Investigation. DOI: 10.1172/JCI201899.

Journal of Clinical Investigationdiabetestype 2 diabetesheart diseaseheart attacksotagliflozinempagliflozin
Source : Journal of Clinical Investigation

Medical Survey

Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Print Article
Show Full Article
Next Story
Recommended For You
NO DATA FOUND

Editorial

Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

View All

Journal Club Today

Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok